1. Sung, H., Ferlay, J. & Siegel, R. L. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. doi:10.3322/caac.21660 (2021).
2. Kennedy, E. M. et al. Inactivation of the human papillomavirus E6 or E7 gene in cervical carcinoma cells by using a bacterial CRISPR/Cas RNA-guided endonuclease. Journal of virology88, 11965-11972, doi:10.1128/jvi.01879-14 (2014).
3. Haedicke, J. & Iftner, T. Human papillomaviruses and cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology108, 397-402, doi:10.1016/j.radonc.2013.06.004 (2013).
4. Bansal, A., Singh, M. P. & Rai, B. Human papillomavirus-associated cancers: A growing global problem. International journal of applied & basic medical research6, 84-89, doi:10.4103/2229-516x.179027 (2016).
5. Wang, J. et al. Blocking activity of the HPV18 virus in cervical cancer cells using the CRISPR/Cas9 system. International journal of clinical and experimental pathology11, 4230-4235 (2018).
6. Leung, T. H. et al. Human papillomavirus E6 protein enriches the CD55(+) population in cervical cancer cells, promoting radioresistance and cancer aggressiveness. The Journal of pathology244, 151-163, doi:10.1002/path.4991 (2018).
7. Ling, K. et al. Gene Targeting of HPV18 E6 and E7 Synchronously by Nonviral Transfection of CRISPR/Cas9 System in Cervical Cancer. Human gene therapy31, 297-308, doi:10.1089/hum.2019.246 (2020).
8. Singh, V., Gohil, N., Ramírez García, R., Braddick, D. & Fofié, C. K. Recent Advances in CRISPR-Cas9 Genome Editing Technology for Biological and Biomedical Investigations. Journal of cellular biochemistry119, 81-94, doi:10.1002/jcb.26165 (2018).
9. Ellis, B. L. et al. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with Nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virology journal10, 74, doi:10.1186/1743-422x-10-74 (2013).
10. Hwang, W. Y. et al. Efficient genome editing in zebrafish using a CRISPR-Cas system. Nature Biotechnology31, 227-229, doi:10.1038/nbt.2501 (2013).
11. Santiago, Y. et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proceedings of the National Academy of Sciences of the United States of America105, 5809-5814, doi:10.1073/pnas.0800940105 (2008).
12. Hu, Z. et al. Disruption of HPV16-E7 by CRISPR/Cas system induces apoptosis and growth inhibition in HPV16 positive human cervical cancer cells. BioMed research international2014, 612823, doi:10.1155/2014/612823 (2014).
13. Chen, X. et al. Amelioration of hemophilia B through CRISPR/Cas9 induced homology-independent targeted integration. bioRxiv, 2021.2003.2018.435908, doi:10.1101/2021.03.18.435908 (2021).
14. Kouranova, E. et al. CRISPRs for Optimal Targeting: Delivery of CRISPR Components as DNA, RNA, and Protein into Cultured Cells and Single-Cell Embryos. Human gene therapy27, 464-475, doi:10.1089/hum.2016.009 (2016).
15. Lau, C. H. & Suh, Y. In vivo genome editing in animals using AAV-CRISPR system: applications to translational research of human disease. 6, 2153, doi:10.12688/f1000research.11243.1 (2017).
16. Yu, W. & Wu, Z. Use of AAV Vectors for CRISPR-Mediated In Vivo Genome Editing in the Retina. Methods in molecular biology (Clifton, N.J.)1950, 123-139, doi:10.1007/978-1-4939-9139-6_7 (2019).
17. Zheng, R. et al. Knockdown of lactate dehydrogenase by adeno-associated virus-delivered CRISPR/Cas9 system alleviates primary hyperoxaluria type 1. 10, e261, doi:10.1002/ctm2.261 (2020).
18. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell63, 1129-1136, doi:10.1016/0092-8674(90)90409-8 (1990).
19. Mighty, K. K. & Laimins, L. A. The role of human papillomaviruses in oncogenesis. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer193, 135-148, doi:10.1007/978-3-642-38965-8_8 (2014).
20. Baliou, S. et al. CRISPR therapeutic tools for complex genetic disorders and cancer (Review). International journal of oncology53, 443-468, doi:10.3892/ijo.2018.4434 (2018).
21. Logan, G. J. & Alexander, I. E. Adeno-associated virus vectors: immunobiology and potential use for immune modulation. Current gene therapy12, 333-343, doi:10.2174/156652312802083639 (2012).
22. Chew, W. L. et al. A multifunctional AAV-CRISPR-Cas9 and its host response. Nature methods13, 868-874, doi:10.1038/nmeth.3993 (2016).
23. Aurnhammer, C. et al. Universal real-time PCR for the detection and quantification of adeno-associated virus serotype 2-derived inverted terminal repeat sequences. Human gene therapy methods23, 18-28, doi:10.1089/hgtb.2011.034 (2012).